Navigation Links
Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors
Date:11/23/2009

BELLEVUE, Wash., Nov. 23 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the election of Akbar Seddigh, Chairman of the Board, Elekta, to a newly created seat on its board of directors. Mr. Seddigh is widely known for guiding numerous medical-product companies, including Elekta, to market leadership.

"The appointment of Akbar Seddigh brings additional strength in business development to the board," said LSO's Chairman of the Board Jeff Himawan. "Mr. Seddigh is a world leader in cancer-therapy business development. He has overseen the emergence of Elekta as the market leader in radiation treatment in oncology -- a much larger market than drug treatment in oncology."

"Akbar Seddigh has been personally instrumental in converting Elekta from a machine vendor to a true cancer-care company," added Llew Keltner, M.D., Ph.D., LSO's President and CEO.

Mr. Seddigh has held managerial positions within Volvo, AB Atomenergi, and the Geological Survey of Sweden. In 1984, he founded the medical-technology company Ortivus, where he was President until the end of the 1990s. He was recruited to Elekta's Board in 1998 and became Chairman in 1999. Elekta is an international medical-technology group, providing clinical solutions, comprehensive information systems, and services for improved cancer care and management of brain disorders. Mr. Seddigh is also Chairman of Inovation Bro (government fund), Hedson Technologies (industrial), and Belekinge Institute of Technology, and Vice-Chairman of the trade group BIO Sweden. He serves on the boards of Swedish companies Formo Services (industrial), Mentice (medical simulation), Affarsstrategerna (venture capital), Biolight (biotech), and Tobii Technology (eye control system).

"Mr. Seddigh's decades of experience, achievements, and network within cancer treatment is highly relevant for making sure LSO's product Aptocine becomes a success in a market that's vastly underserved," said Martin Olin, LSO board member and long-time Seddigh associate.

"Working on the board of Light Sciences Oncology will be one of the most interesting and exciting assignments of my career," commented Mr. Seddigh. "I look forward to helping LSO and Aptocine achieve success and leadership in the cancer-treatment community."

About Light Sciences Oncology

Light Sciences Oncology (LSO) is developing Aptocine(TM) (talaporfin sodium) for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia (BPH). Aptocine is a water-soluble drug targeted by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment of patients in a Phase 3 trial of Aptocine in hepatocellular carcinoma (HCC) and is currently enrolling patients in a Phase 3 trial for metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials in benign prostatic hyperplasia (BPH), or enlargement of the prostate, and has clinical or preclinical programs in cardiovascular, ophthalmic, and dermatologic diseases. LSO's development organization oversees engineering, clinical trials, manufacturing, and regulatory/legal affairs. The company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally capable and efficient team.


Contacts

Robert M. Littauer
Vice President, Chief Financial Officer and Treasurer
1-425-957-8900
bobl@lsoncology.com

Llew Keltner, M.D., Ph.D.
President and CEO
1-425-957-8900
dr_llew@lsoncology.com


Website: www.lsoncology.com

Aptocine(TM) is a trademark of Light Sciences Oncology, Inc.

SOURCE Light Sciences Oncology, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
2. OCTANes Medical Device & Investor Forum Highlights Key Trends, Investment Opportunities
3. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
4. Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting
5. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
6. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
7. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
8. Burton Medicals New Diagnostic Examination Light, the AIM LED Provides 10 Percent More Illumination and 10 Times Greater Lamp Life
9. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
10. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
11. Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... YORK , March 29, 2017 Global intravenous ... US$ 3 billion by 2021, growing at a CAGR of ... iron prescribed by a doctor to treat anemia or other ... iron level in the body. However, in some cases, oral ... the body and intravenous (IV) iron therapy comes into the ...
(Date:3/29/2017)... March 29, 2017  BioSpecifics Technologies Corp. (NASDAQ: ... to develop collagenase based-therapies with a first in ... as XIAFLEX ®  in the U.S. and Xiapex ... a corporate overview at the upcoming 16 th ... 5, 2017 at 8:00 a.m. ET in ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced the ... Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in Italy ... value in 2016. There are currently three proton therapy centers in ... more patients. In Italy , the first patients were ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 2017 , ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower ... college students who have participated in the program every summer. The 2017 Serve, ... applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , “I have ...
(Date:3/29/2017)... Rouge, Louisiana (PRWEB) , ... March 29, 2017 ... ... HeartBoost in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers ... at Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over the ...
(Date:3/29/2017)... Mt. Horeb, WI (PRWEB) , ... March 29, 2017 , ... ... her patients on early orthodontic treatment and accepting new pediatric patients, with or without ... can help young patients have a better orthodontic outcome and experience. When patients receive ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a ... the finalization of the company’s executive management team with prominent executives from both inside ... Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty ...
(Date:3/29/2017)... Ca (PRWEB) , ... March 29, 2017 , ... Immunotherapy ... a growing number of cancers and is touted to be the next revolution in ... thus far, has been in the form of immune checkpoint inhibitors such as PD-1 ...
Breaking Medicine News(10 mins):